Search
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Bitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
AS1409
go.drugbank.com/drugs/DB05182InvestigationalIt is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.
NV-07a
go.drugbank.com/drugs/DB05845ExperimentalNV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigational[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Lanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedLanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147ApprovedA condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinuc...
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug. … [L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalAlmost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. … Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).